No profile data available.
Heron Therapeutics, Inc. (HRTX) is a healthcare company in the digestive system treatment drugs industry, based in Cary, United States, with about 128 full-time employees.
It reported revenue of $154.90 million for fiscal year 2025, up 7.4% from fiscal year 2024, and net income of -$20.20 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $37.67 million, up 1.3% from a year before. Its market capitalization was $77.10 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Heron Therapeutics reported $154.90 million in revenue for fiscal year 2025, up 7.4% from $144.29 million in fiscal year 2024. In Q2 2026 revenue was $37.67 million.
$77.10 million as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Phathom Pharmaceuticals, Inc. (PHAT), Palisade Bio, Inc. (PALI), Cumberland Pharmaceuticals Inc. (CPIX), Evoke Pharma, Inc. (EVOK).